X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB FRESENIUS KABI ONCO. UNICHEM LAB/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 278.7 22.1 1,259.2% View Chart
P/BV x 0.6 3.1 20.6% View Chart
Dividend Yield % 2.6 0.0 -  

Financials

 UNICHEM LAB   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
FRESENIUS KABI ONCO.
Mar-13
UNICHEM LAB/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs382176 217.0%   
Low Rs23479 298.2%   
Sales per share (Unadj.) Rs116.337.7 308.6%  
Earnings per share (Unadj.) Rs-18.95.1 -371.5%  
Cash flow per share (Unadj.) Rs-11.76.7 -174.6%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.60-  
Book value per share (Unadj.) Rs381.042.5 895.6%  
Shares outstanding (eoy) m70.34158.23 44.5%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.63.4 78.4%   
Avg P/E ratio x-16.325.0 -65.2%  
P/CF ratio (eoy) x-26.218.9 -138.6%  
Price / Book Value ratio x0.83.0 27.0%  
Dividend payout %-26.40-   
Avg Mkt Cap Rs m21,66820,135 107.6%   
No. of employees `0002.31.2 197.9%   
Total wages/salary Rs m2,006703 285.3%   
Avg. sales/employee Rs Th3,587.85,176.2 69.3%   
Avg. wages/employee Rs Th880.0610.4 144.2%   
Avg. net profit/employee Rs Th-583.7699.6 -83.4%   
INCOME DATA
Net Sales Rs m8,1805,963 137.2%  
Other income Rs m61018 3,389.4%   
Total revenues Rs m8,7905,981 147.0%   
Gross profit Rs m-1,3201,430 -92.3%  
Depreciation Rs m505258 195.9%   
Interest Rs m80-26 -308.1%   
Profit before tax Rs m-1,2951,216 -106.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m33342 9.8%   
Profit after tax Rs m-1,331806 -165.1%  
Gross profit margin %-16.124.0 -67.3%  
Effective tax rate %-2.628.1 -9.2%   
Net profit margin %-16.313.5 -120.4%  
BALANCE SHEET DATA
Current assets Rs m23,3185,102 457.1%   
Current liabilities Rs m4,6352,385 194.3%   
Net working cap to sales %228.445.6 501.4%  
Current ratio x5.02.1 235.2%  
Inventory Days Days122150 81.2%  
Debtors Days Days121113 107.2%  
Net fixed assets Rs m8,1635,148 158.6%   
Share capital Rs m141158 88.9%   
"Free" reserves Rs m26,6606,556 406.7%   
Net worth Rs m26,8016,732 398.1%   
Long term debt Rs m3952 0.3%   
Total assets Rs m31,89010,388 307.0%  
Interest coverage x-15.2-45.8 33.1%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.30.6 44.7%   
Return on assets %-3.97.5 -52.2%  
Return on equity %-5.012.0 -41.5%  
Return on capital %-4.514.6 -31.1%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m4,3565,298 82.2%   
Fx outflow Rs m01,772 0.0%   
Net fx Rs m4,3563,525 123.6%   
CASH FLOW
From Operations Rs m-1,1231,274 -88.2%  
From Investments Rs m16,487-1,204 -1,369.1%  
From Financial Activity Rs m-8,811-196 4,493.3%  
Net Cashflow Rs m6,552-126 -5,187.6%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 15.1 0.3 5,033.3%  
FIIs % 3.0 9.6 31.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 9.1 348.4%  
Shareholders   20,176 42,599 47.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   ALKEM LABORATORIES  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Banking and Automobile Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.

Related Views on News

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Apr 23, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS